
Universal Health Realty Income Trust is upgraded to 'Buy' with a $39.50/share price target after the stock fell to my suggested entry point. UHT's Q2 2026 FFO rose 5.88% year-on-year, driven by lower interest costs, not revenue growth, and the dividend remains well-covered with an 8.1% yield. Key risks include UHS tenant concentration (40% of revenue), expiring interest rate swaps, and upcoming lease expirations at two medical centers.










